Trials / Recruiting
RecruitingNCT06618235
Trial of THEO-260 in Ovarian Cancer Patients
A Phase I/IIa, Open-label, Dose Finding, Safety, Tolerability and Exploratory Trial of THEO-260 in Patients With High Grade Serous or Endometrioid Ovarian Cancer
- Status
- Recruiting
- Phase
- Phase 1 / Phase 2
- Study type
- Interventional
- Enrollment
- 44 (estimated)
- Sponsor
- Theolytics Limited · Industry
- Sex
- Female
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
A research study evaluating a new oncolytic virus, THEO-260, in patients with advanced ovarian cancer. The trial will investigate different doses of THEO-260 administered intravenously to identify a dose that is safe, well tolerated, and exhibits preliminary evidence of anti tumour activity.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | THEO-260 | Oncolytic Virus |
Timeline
- Start date
- 2024-09-24
- Primary completion
- 2028-06-01
- Completion
- 2028-06-01
- First posted
- 2024-10-01
- Last updated
- 2026-04-14
Locations
4 sites across 2 countries: Spain, United Kingdom
Source: ClinicalTrials.gov record NCT06618235. Inclusion in this directory is not an endorsement.